Lisata Therapeutics Stock Today
| LSTA Stock | USD 3.85 0.28 7.84% |
Performance8 of 100
| Odds Of DistressLess than 17
|
Lisata Therapeutics is trading at 3.85 as of the 6th of January 2025, a 7.84% up since the beginning of the trading day. The stock's open price was 3.57. Lisata Therapeutics has less than a 17 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 7th of December 2024 and ending today, the 6th of January 2025. Click here to learn more.
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease andor promote the regeneration of damaged tissue. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. The company has 8.39 M outstanding shares of which 19.13 K shares are now shorted by private and institutional investors with about 1.79 trading days to cover. More on Lisata Therapeutics
Moving against Lisata Stock
Lisata Stock Highlights
| CEO President | BSc B |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Lisata Therapeutics (LSTA) is traded on NASDAQ Exchange in USA. It is located in 110 Allen Road, Basking Ridge, NJ, United States, 07920 and employs 25 people. Lisata Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.32 M. Lisata Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.39 M outstanding shares of which 19.13 K shares are now shorted by private and institutional investors with about 1.79 trading days to cover.
Lisata Therapeutics currently holds about 72.99 M in cash with (20.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Lisata Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Lisata Therapeutics is $32.32 Million. Lisata Therapeutics secures 19.12 % of its outstanding shares held by insiders and 9.07 % owned by institutional investors. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Lisata Ownership Details
Lisata Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Lisata Therapeutics market risk premium is the additional return an investor will receive from holding Lisata Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1006 | |||
| Jensen Alpha | 0.4802 | |||
| Total Risk Alpha | 0.421 | |||
| Sortino Ratio | 0.1496 |
Lisata Stock Against Markets
Lisata Therapeutics Corporate Management
| Kristen MD | Executive Officer | Profile | |
| Gail Holler | Vice Resources | Profile | |
| James Nisco | Treasurer, Finance | Profile | |
| Tariq Imam | Vice Counsel | Profile | |
| Ian MBA | Inc NeoStem | Profile | |
| Gregory Berkin | Chief Officer | Profile | |
| John Menditto | Vice Communications | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.